The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Prognostic drivers in AML and MDS
Genomic sequencing studies are needed to gain a deeper understanding of the pathogenesis of myeloid malignancies. Ilaria Iacobucci, PhD, St. Jude Children’s Research Hospital, Memphis, TN, discusses the integrated genome-wide mutational/transcriptomic analysis performed on a large cohort of adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) samples to accurately define subtypes of diagnostic, prognostic and therapeutic relevance. Genome/transcriptome sequencing and gene expression analysis enabled the definition of subtypes and constellations of mutations in AML and MDS, which have prognostic significance that surpasses previous gene panel-based classifications. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
